Mode
Text Size
Log in / Sign up

Childhood B Acute Lymphoblastic Leukemia

Part of Cancer

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Childhood B Acute Lymphoblastic Leukemia

5 trials tracked for Childhood B Acute Lymphoblastic Leukemia: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 227 citations.

5Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 4 Phase 1 1
  1. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 227 cited
  2. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 102 cited
  3. Phase 3 Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed · 47 cited
  4. Phase 3 Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed
  5. Phase 1 Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Childhood B Acute Lymphoblastic Leukemia: what the trials found

Clinical evidence for Childhood B Acute Lymphoblastic Leukemia (ALL) includes data on the administration of Cyclophosphamide across multiple phases and sample sizes [1, 4, 5]. Research has also identified specific outcomes regarding health-related quality of life interventions during treatment 1.

In patients undergoing therapy for Average Risk (AR) ALL, studies have characterized Vincristine-associated neuropathy 12 months post-therapy, noting values of -1.12 on the right and -1.19 on the left 2.

For the clinician treating this condition

  • Cyclophosphamide is utilized in various clinical contexts for pediatric ALL [1, 4, 5].
  • Vincristine-associated neuropathy can be quantified 12 months post-therapy in patients with Average Risk (AR) ALL 2.

AI synthesis of 2 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.

Research across Cancer

Related studies from across the Cancer family.

Anti-CD19 shRNA-engineered CAR-T cells achieve an 88% overall response rate in B-cell acute lymphoblastic leukemia
Oncology Meta-analysis
Anti-CD19 shRNA-engineered CAR-T cells achieve an 88% overall response rate in B-cell acute lymphoblastic leukemia CAR-T Cells Show Promise for B-cell Acute Lymphoblastic Leukemia
This meta-analysis evaluates anti-CD19 shRNA-engineered CAR-T cells (interleukin-6 knockdown) for patients with B-cell acute lymphoblastic l…
New research into modified CAR-T cells shows high response rates in patients with a specific type of leukemia while managing serious side ef…
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
Allergy & Immunology Sys. Review
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction
Diabetes & Endocrinology Sys. Review
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction Fertility preservation options carry risks for female leukemia patients
This review examines fertility preservation strategies for female patients with leukemia. The authors note that oocyte or embryo cryopreserv…
Fertility preservation strategies for female leukemia patients face safety concerns like disease reintroduction and contamination risks that…
Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing
Drug Pipeline Sys. Review
Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing New review looks at using genetic tests to adjust cancer drug doses for kids
This narrative review examines the role of pharmacogenomic biomarkers and genotype-guided dose adjustments in pediatric B-cell acute lymphob…
A recent review suggests that checking specific genes before treatment can help doctors give the right amount of chemotherapy to children wi…
Review of a case of Down syndrome T-ALL with complex karyotype and treatment response
Pediatrics Sys. Review
Review of a case of Down syndrome T-ALL with complex karyotype and treatment response Boy with Down syndrome beats rare leukemia after tailored chemo
This narrative review and case report describes a 7-year-old boy with Down syndrome and T-cell acute lymphoblastic leukemia treated with AIE…
A 7-year-old with Down syndrome and a rare T-cell leukemia achieved remission after tailored chemotherapy, despite severe complications.
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia
Oncology RCT
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia Adding a weekly shot to a daily leukemia pill boosts deep remission rates
This phase 3 trial compared nilotinib monotherapy against nilotinib combined with pegylated interferon alfa-2a in patients with newly diagno…
A weekly injection added to a daily pill helped more newly diagnosed CML patients reach deep remission, but it also caused more side effects…
Systematic review and meta-analysis finds high prevalence of ocular manifestations in leukemia patients
Hematology Meta-analysis
Systematic review and meta-analysis finds high prevalence of ocular manifestations in leukemia patients Leukemia patients face eye risks that doctors must spot early now
This systematic review and meta-analysis of 1016 patients with leukemia found a 42% prevalence of overall ocular manifestations.
New data shows almost half of leukemia patients have eye issues, so regular eye checks are essential for better care
Meta-analysis links perinatal factors to childhood acute leukemia risk
Hematology Meta-analysis
Meta-analysis links perinatal factors to childhood acute leukemia risk Perinatal factors linked to higher leukemia risk in children
This systematic review and meta-analysis of 85 studies examined perinatal factors and childhood acute leukemia risk.
A large analysis of 85 studies finds links between birth weight, maternal history, and cesarean sections with childhood leukemia risk.
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL
Allergy & Immunology Cohort
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL New Leukemia Treatment Keeps Adult Patient Cancer Free For Seven Years
This retrospective observational analysis of a single clinical case describes an adult patient with early-relapsed, chemorefractory B-cell a…
A new dual-targeted therapy helped an adult with tough leukemia stay cancer-free for seven years after standard treatments failed.
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
Allergy & Immunology Sys. Review
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Meta-analysis links DNA repair gene polymorphisms to leukemia risk across 54 studies
Oncology Meta-analysis
Meta-analysis links DNA repair gene polymorphisms to leukemia risk across 54 studies DNA Repair Flaws May Raise Leukemia Risk
This meta-analysis of 54 studies examines associations between DNA repair gene polymorphisms and leukemia risk.
Imagine your cells have a built-in repair crew that fixes mistakes in your DNA every day.
Review compares 68Ga-pentixafor and 18F-FDG PET/CT in a single CLL patient
Oncology Sys. Review
Review compares 68Ga-pentixafor and 18F-FDG PET/CT in a single CLL patient A New Scan Spots a Tricky Blood Cancer Far More Clearly
This case report and review of literature evaluates diagnostic performance of 68Ga-pentixafor versus 18F-FDG PET/CT in a 60-year-old woman w…
A new PET scan tracer spots chronic lymphocytic leukemia more clearly than standard imaging, helping doctors see disease extent in patients …